FDA Approves Expanded Indication For Takeda's VONVENDI In Von Willebrand Disease
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK, TKPHF, 4502.T) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI [von Willebrand factor (Recombinant)]. The expanded indication now inc
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief